J&J Has Kenvue IPO Roadshow In One Lane, Potentially Long Road For Talc Litigation In Other

Roadshow stated for IPO planned for before end of 2023 of 151.2m shares of Kenvue common stock currently expected at between $20 and $23 per share. Analysts positive on IPO but caution launch wouldn’t come problem-free.

• Source: Shutterstock

Johnson & Johnson is on the road to show investors the value of the consumer health business it plans to spin out this year, Kenvue Inc., while a court considering the firm’s second bankruptcy filing for a subsidiary it created to handle its talc-product liabilities will say hit the road or accept the proposal.

More from Legal

More from Policy & Regulation